학술논문
Validation of biomarkers of aging
Document Type
Review Paper
Author
Moqri, Mahdi; Herzog, Chiara; Poganik, Jesse R.; Ying, Kejun; Justice, Jamie N.; Belsky, Daniel W.; Higgins-Chen, Albert T.; Chen, Brian H.; Cohen, Alan A.; Fuellen, Georg; Hägg, Sara; Marioni, Riccardo E.; Widschwendter, Martin; Fortney, Kristen; Fedichev, Peter O.; Zhavoronkov, Alex; Barzilai, Nir; Lasky-Su, Jessica; Kiel, Douglas P.; Kennedy, Brian K.; Cummings, Steven; Slagboom, P. Eline; Verdin, Eric; Maier, Andrea B.; Sebastiano, Vittorio; Snyder, Michael P.; Gladyshev, Vadim N.; Horvath, Steve; Ferrucci, Luigi
Source
Nature Medicine. 30(2):360-372
Subject
Language
English
ISSN
1078-8956
1546-170X
1546-170X
Abstract
The search for biomarkers that quantify biological aging (particularly ‘omic’-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.
Robust validation of biomarkers of aging will be critical to their clinical translation; here, authors review the key challenges and propose recommendations to overcome them.
Robust validation of biomarkers of aging will be critical to their clinical translation; here, authors review the key challenges and propose recommendations to overcome them.